Individuals are given two vaccinations at the 12-13 years National Immunisation Program schedule point:

  • Gardasil 9 protects against HPV (human papillomavirus)
  • Boostrix protects against diphtheria, tetanus, whooping cough (dTpa)

AusVaxSafety has been conducting surveillance of the vaccines given at the 12-13 years schedule point on a continuous basis since 2019. The analysis has remained constant over this time and not identified any safety concerns.

The latest medical attendance rate for the 12-13 years schedule point is below and will be updated on a quarterly basis. Note: Dose 2 of HPV vaccine is no longer funded under the National Immunisation Program; therefore, the dose 2 HPV data below are no longer updated. AusVaxSafety has retained the display of historical HPV dose 2 data as a reference.

In April 2022, the vaccine safety survey used for active surveillance of vaccines on the National Immunisation Program was updated to replicate the vaccine safety survey used for COVID-19 and seasonal influenza vaccine surveillance to allow for better comparison across all vaccines monitored. Data displayed on this page show analysis of the new survey. Reassuringly, data from the new vaccine safety survey are comparable to the rates reported in the previous survey.

More detailed safety data from the 12-13 years schedule point is available from the 2022 Vaccine Safety in Australia AusVaxSafety Summary Report below.

Access AusVaxSafety data from the 12-13 years schedule point for 2022

Last updated March 2024